See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Ozzy Osbourne
Donald Trump
Social Media
Crime
Artificial Intelligence
Natural Disasters
Housing
Republican Party
Infrastructure
Cricket
Democratic Party
Drug Hunter image

News from Drug Hunter

If you want to know if Drug Hunter is credible or reliable, look no further. We rank Drug Hunter as Unknown factuality. Find out more about our methodology here.

Information about Drug Hunter

Where is Drug Hunter located?Drug Hunter's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Drug Hunter News

Rwanda: Lenacapavir Offers Hope Against HIV, Now the World Must Act
United Nations

Rwanda: Lenacapavir Offers Hope Against HIV, Now the World Must Act

100% Center coverage: 1 sources
A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.See the Story
GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters
Diabetes

GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters

100% Center coverage: 1 sources
(MedPage Today) -- SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric surgery, a retrospective analysis found. In 568 patients who underwent bariatric surgery, those who...See the Story
Classics in Drug Discovery: A History of the Statins

Classics in Drug Discovery: A History of the Statins

13 years after the loss of patent exclusivity, atorvastatin (Lipitor®) remains the highest grossing small molecule in pharmaceutical history, redefining what a “blockbuster” drug can be. However, this commercial success was just the dramatic exclamation point to the statin story that encompassed Nobel prizes, blockbuster drugs, and 30+ years of target biology inquiry and drug discovery. This review will highlight the history of, and challenges a…Read Article

Two Divergent Approaches to Drugging IRF5

Targeting transcription factors for therapeutic intervention is a challenge in small molecule drug discovery. However excitement around IRF5, a key immune system regulator that is implicated in lupus and rheumatoid arthritis, has inspired renewed effort. This review highlights how two companies, HotSpot Therapeutics and Kymera Therapeutics, are tackling IRF5 with distinct strategies. Both approaches show promise by reducing inflammation and dise…Read Article

Simplifying Synthesis with Radical Cross-Coupling

In this Flash Talk, Phil Baran presents novel synthetic methodologies that harness the reactivity of radical intermediates to unlock more efficient and previously inaccessible synthetic routes. In this article, Phil provides answers to all questions from the seminar, including those that couldn’t be addressed during the live session. Phil highlights how his group rapidly constructs highly valuable, complex saturated heterocycles and discussed th…Read Article

Targeting 17β-HSD13: Emerging Patent Landscape in Fibrosis and NASH

17β-HSD13 is a member of a 15-enzyme family involved in the metabolism of steroid hormones, fatty acids, cholesterol, and bile acids. It is a promising target for NAFLD and NASH, supported by GWAS data showing that loss-of-function variants reduce liver enzyme levels and disease risk. Clinical validation came from Arrowhead’s ARO-HSD, an siRNA that lowered serum ALT. While the full function of 17β-HSD13 remains unclear, it acts on lipid substrat…Read Article

STAT6: A Challenging Target Gains Traction Utilizing Degraders for Th2-Driven Disease

STAT6, once deemed undruggable, is now being targeted through protein degradation. This article highlights recent developments including Kymera’s KT‑621, a cereblon-based STAT6 degrader, that entered Ph. 1 and has shown >95% knockdown of STAT6 as well as Th2 biomarker suppression. It also surfaces preclinical programs from Nurix and the University of Michigan. STAT6 degradation marks a shift in targeting transcription factors for immune and canc…Ann Arbor · Ann ArborRead Article

Do LRRK2 Heterobifunctional Degraders Mitigate “On-Target” Toxicity?

LRRK2 kinase inhibitors promised to revolutionize Parkinson’s disease therapy—until preclinical lung toxicity, believed to be on-target, halted their progress. Heterobifunctional degraders now offer a fresh approach. By fully degrading the LRRK2 protein these molecules demonstrate enhanced efficacy. Additionally, initial results show the potential avoidance of the lung fibrosis seen with kinase inhibitors. This review provides a brief history of…Read Article

RNA-Targeting Splice Modulators Target Difficult to Treat CNS Disorders

Once thought undruggable, RNA is now fair game for small molecules. Since the approval of Risdiplam, the first FDA-approved RNA-targeting small molecule, there has been a wave of small molecule splice modulators in preclinical and clinical development. These small molecules act upstream of translation, modulating gene expression via RNA, with the potential to treat repeat expansion and splicing-driven diseases. This review focuses on diseases of…Read Article

Are RIPTACs the Small Molecule Answers to ADCs?

This article provides a brief overview of RIPTACs™, a unique heterobifunctional small molecule modality capable of targeting and selectively killing cells via the formation of a ternary complex between a cell-type specific TP (target protein), the RIPTAC™ molecule, and a pan-essential effector protein (EP) that is required for cell survival. We also highlight Halda’s development of HLD-0915, a first-to-clinic RIPTAC™ therapeutic, targeting mCRPC…Read Article

The Sulfoximine Group: A Rising Star in Medicinal Chemistry

Sulfoximines are versatile functional groups that can offer opportunities for improving the physicochemical and ADME properties of drug candidates. In this article, we present key synthetic routes for the introduction of sulfoximine motifs and showcase real-world case studies where scientists have leveraged sulfoximine groups as bioisosteres of sulfones and sulfonamides. We also discuss the wide application of sulfoximine functional groups in co…Read Article

Breaking News Topics Related to Drug Hunter

United States icon

United States

News
For You
SearchBlindspotLocal